Outlook on ‘Microphysiological Systems (MPS) – The future of pre-clinical R&D’ that outlines the challenges with traditional drug testing, alternatives to the traditional methods, and the current and future perspective on MPS technologies.
With a ~90% failure rate of drugs in clinical trials, the biopharma R&D continues to operate with substandard efficiency. The traditional drug testing methods (in-vitro and in-vivo) often fail to translate into clinical observations. Therefore, there is a high unmet need to develop in-vitro systems offering improved clinical translation that can potentially reduce late-stage failures, thereby saving time and cost of drug development.
Microphysiological systems offer one such solution that can potentially improve the in vitro-in vivo and in vitro-clinical correlation. While this space has taken about a decade to evolve, the recent developments in the MPS platforms has increasingly captured attention from pharma cos, CROs and regulatory agencies. With this solid foundation resulting from years of research, the MPS space is at a tipping point that can potentially transform the biopharma drug discovery R&D.
MP group, with its deep understanding of MPS space and >3 decades of global biopharma experience, will be happy to learn more about your current and future R&D priorities and catalyze the journey towards the adoption of prudent technologies to improve the overall R&D efficiency.
May I request an introductory call with you or relevant members of your team in the coming days? I will be happy to set up the call at your convenient time.
Please download the presentation here – ‘Microphysiological Systems (MPS) – The future of pre-clinical R&D’.